Seminars in ophthalmology · 2025
Clinical Dilemmas in Coexisting Ocular Surface Disease and Glaucoma.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Singh Archana, Arora Ekta, Tuteja Sahib Y, Singh Dilpreet
Аннотация
BACKGROUND: Ocular surface disorders (OSD) and glaucoma often co exist. Intraocular pressure lowering medications and preservatives used with them may lead to ocular surface toxicity and drug induced cicatrizing conjunctivitis (DICC). Surgical management of glaucoma helps in reducing the requirement of topical anti glaucoma drugs but, at the same time, may also disrupt the ocular surface. On the other hand, medical therapies and surgeries required for management of OSD often lead to secondary glaucoma, thereby inducing a vicious cycle.
METHODS: Relevant articles (English only) up to January, 2025 were searched from PubMed and summarized.
RESULTS: Our review discusses the epidemiology, various diagnostic, therapeutic and surgical aspects of this interlinked scenario in a comprehensive manner. Medical therapies (steroids) utilized for controlling inflammation in OSD and related steroid induced glaucoma, anti glaucoma medications (and their preservatives) causing OSD and their respective available alternatives have been discussed in individual sections. Similarly, glaucoma surgeries causing OSD, surgeries for OSD leading to secondary glaucoma and the surgical considerations with possible alternatives, including the novel therapies, have been reviewed. The future directions, along with the role of gut microbiome in ocular diseases and the various therapeutic agents/interventions under clinical investigations, are also explored.
CONCLUSION: A deeper understanding of the interplay of different factors in these co-morbid conditions will help in breaking the vicious cycle induced and therefore, in offering more effective treatment. Recommendations for clinicians have been suggested to help optimize the treatment provided to this specific patient cohort of 'OSD and glaucoma'.
METHODS: Relevant articles (English only) up to January, 2025 were searched from PubMed and summarized.
RESULTS: Our review discusses the epidemiology, various diagnostic, therapeutic and surgical aspects of this interlinked scenario in a comprehensive manner. Medical therapies (steroids) utilized for controlling inflammation in OSD and related steroid induced glaucoma, anti glaucoma medications (and their preservatives) causing OSD and their respective available alternatives have been discussed in individual sections. Similarly, glaucoma surgeries causing OSD, surgeries for OSD leading to secondary glaucoma and the surgical considerations with possible alternatives, including the novel therapies, have been reviewed. The future directions, along with the role of gut microbiome in ocular diseases and the various therapeutic agents/interventions under clinical investigations, are also explored.
CONCLUSION: A deeper understanding of the interplay of different factors in these co-morbid conditions will help in breaking the vicious cycle induced and therefore, in offering more effective treatment. Recommendations for clinicians have been suggested to help optimize the treatment provided to this specific patient cohort of 'OSD and glaucoma'.